



Attorney Docket No.: 5686.200-US

RECEIVED

JUL 26 2001

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Application No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that this reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than this listed exists or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed. The reference is as follows:


1. Chung et al, Chem. Commun. "Quinoxalino-fused sultines and their application in Diels-Alder reactions" pgs. 205-206 (1997)

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

The supplemental information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: 18 July 2001

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



Attorney Docket No.: 5686.200-US

1614  
**RECEIVED**

JUL 26 2001  
PATENT

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists |

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box DD  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD  
Commissioner for Patents  
Washington, DC 20231

on 18 July 2001.

Sylvia Gonzalez  
(name of person mailing paper)

*Sylvia Gonzalez*  
(signature of person mailing paper)